Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cleopatra Hospital CoCAI:CLHO +2.32%92 Return-on-Tangible-Asset is 4.63% as of Mar. 2026, which is 61% below its 10-year median of 12.01. GuruFocus rates CAI:CLHO with a GF Score™ of 92/100 and a GF Value™ of E£14.12 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Cleopatra Hospital Co ranks better than 73.94% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cleopatra Hospital Co's annualizedNet Income for the quarter that ended in Mar. 2026 was E£472 Mil. Cleopatra Hospital Co's average total tangible assets for the quarter that ended in Mar. 2026 was E£10,210 Mil. Therefore, Cleopatra Hospital Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 4.63%.
The historical rank and industry rank for Cleopatra Hospital Co's Return-on-Tangible-Asset or its related term are showing as below:
CAI:CLHO'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.29 Med: 12.01 Max: 15.03
Current: 7.86
During the past 11 years, Cleopatra Hospital Co's highest Return-on-Tangible-Asset was 15.03%. The lowest was 7.29%. And the median was 12.01%.
CAI:CLHO's Return-on-Tangible-Asset is ranked better than 73.94% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs CAI:CLHO: 7.86
Cleopatra Hospital Co (CAI:CLHO) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Cleopatra Hospital Co Return-on-Tangible-Asset Related Terms
Cleopatra Hospital Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Cleopatra Hospital Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cleopatra Hospital Co Return-on-Tangible-Asset Chart
CAI:CLHO vs HCA, THC, DVA: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Cleopatra Hospital Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleopatra Hospital Co Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cleopatra Hospital Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Cleopatra Hospital Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.63% mean?
Cleopatra Hospital Co (CAI:CLHO) has a Return-on-Tangible-Asset of 4.63% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cleopatra Hospital Co and its competitors. This is 61% below median its historical median of 12.01. Over the past decade, Cleopatra Hospital Co's Return-on-Tangible-Asset has ranged from 7.29 to 15.03. According to the industry distribution chart, Cleopatra Hospital Co ranks #178 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 26.1%.
Is Cleopatra Hospital Co's Return-on-Tangible-Asset too high?
Cleopatra Hospital Co's current Return-on-Tangible-Asset of 4.63% is 61% below median its 10-year median of 12.01. Over the past 10 years, this metric has ranged from a low of 7.29 to a high of 15.03. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.43. Cleopatra Hospital Co's value of 4.63% is 90.5% above this industry median. Based on the distribution chart, Cleopatra Hospital Co ranks #178 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cleopatra Hospital Co has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cleopatra Hospital Co's Return-on-Tangible-Asset compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cleopatra Hospital Co ranks #178 out of 683 companies for Return-on-Tangible-Asset. This puts Cleopatra Hospital Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.43. Cleopatra Hospital Co's value of 4.63% is 90.5% above this benchmark. Historically, Cleopatra Hospital Co's own Return-on-Tangible-Asset has ranged from 7.29 to 15.03 over the past decade. While the company's 10-year median is 12.01 vs. the industry median of 2.43, Cleopatra Hospital Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cleopatra Hospital Co's current Return-on-Tangible-Asset of 4.63% is 90.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cleopatra Hospital Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleopatra Hospital Co's current Return-on-Tangible-Asset is 4.63%, which is 61% below median its own 10-year median of 12.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleopatra Hospital Co stock overvalued right now?
Based on GuruFocus' analysis, Cleopatra Hospital Co (CAI:CLHO) is currently considered Modestly Overvalued. The stock's GF Value™ is E£14.12, compared to a current price of E£16.75 — trading 18.6% above its estimated fair value. The current Return-on-Tangible-Asset is 4.63%, which is 61% below median its 10-year median of 12.01 and 90.5% above the Healthcare Providers & Services industry median of 2.43. Cleopatra Hospital Co's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Cleopatra Hospital Co (CAI:CLHO), the current Return-on-Tangible-Asset is 4.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cleopatra Hospital Co (CAI:CLHO) Overvalued in 2026?
Based on GuruFocus' analysis, Cleopatra Hospital Co stock appears to be overvalued.
The current stock price of E£16.75 is trading 18.6% above its estimated GF Value™ of E£14.12.
GuruFocus considers Cleopatra Hospital Co to be Modestly Overvalued.
Key valuation signals for CAI:CLHO:
Return-on-Tangible-Asset: 4.63% (61% below median its 10-year median of 12.01)
GF Value™: E£14.12 vs. price of E£16.75 (18.6% above fair value)
Industry Position: 90.5% above the Healthcare Providers & Services median (#178 of 683)
No single metric tells the full story. See the CAI:CLHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cleopatra Hospital Co establishes a private hospital to provide modern health and medical services, in addition to medical care for inpatients. The company's segments include Cleopatra Hospital Company, Cairo Specialised Hospital, Nile Badrawy Hospital, Al Shrouk Hospital, CHG Medical Services, CHG Pharma for Pharmacy Management, CHG for Hospitals Company, Queens Hospital, ElKateb Hospital, Bedaya El Gedida Company for Medical Centers and Hospitals, CHG SKY Hospital, and Cleopatra Heaven.
92GF Score
Get the complete analysis for CAI:CLHO
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:CLHO has been successfully added to your 
